MannKind Breathes Easier After FDA Diabetes Safety Guidance

MannKind is reassuring investors that its fast-acting inhaled insulin product Afresa, due for a U.S. filing soon, is likely to satisfy new FDA guidelines for cardiovascular safety of diabetes drugs